BiomX (PHGE) Stock Price, News & Analysis

Company Overview

BiomX (NYSEAMERICAN:PHGE) is a clinical-stage biotechnology company dedicated to developing precision microbiome therapies using bacteriophages. The company’s proprietary platform combines phage discovery, engineering and formulation to target specific bacterial strains implicated in human diseases, with an initial emphasis on gastrointestinal disorders and dermatological conditions. By leveraging endolysins and tailored phage cocktails, BiomX aims to restore healthy microbial balance and offer alternatives to traditional antibiotics and immunomodulatory treatments.

Founded as a spin-out from leading Israeli research institutions, BiomX has assembled a multidisciplinary research pipeline that addresses unmet medical needs in inflammatory bowel disease (IBD) and acne vulgaris. The company’s lead programmes include a phage cocktail for ulcerative colitis and Crohn’s disease, advancing through Phase II clinical trials, as well as phage formulations targeting Cutibacterium acnes for moderate to severe acne. BiomX employs advanced bioinformatics and high-throughput screening to identify novel phage candidates and optimize their therapeutic potential.

BiomX operates research and development facilities in Israel and collaborates with contract research organizations and academic partners across North America and Europe. These strategic alliances support clinical trial execution, manufacturing scale-up and regulatory submissions in multiple jurisdictions. The company’s manufacturing capabilities include a state-of-the-art phage production facility, ensuring consistency and quality in its biologic therapeutics.

The executive leadership team at BiomX brings together expertise in microbiology, drug development and regulatory affairs. Guided by a board of directors with seasoned professionals from the biotechnology and pharmaceutical industries, the company maintains a focus on scientific rigor and patient‐centric development. BiomX continues to advance its clinical programmes while exploring additional indications where precision phage therapy may offer clinical benefit.

Key Stats

• Today's Range: $0.38 to $0.42
• 50-Day Range: $0.38 to $0.56
• 52-Week Range: $0.34 to $3.58
• Volume: 947,566 shs
• Average Volume: 3.03 million shs
• Market Capitalization: $10.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Buy

BiomX Stock Analysis - MarketRank™

BiomX scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

BiomX has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BiomX are expected to decrease in the coming year, from ($2.77) to ($2.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BiomX is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BiomX is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BiomX has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.38% of the float of BiomX has been sold short.

Short Interest Ratio / Days to Cover

BiomX has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BiomX has recently decreased by 20.52%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BiomX does not currently pay a dividend.

Dividend Growth

BiomX does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.38% of the float of BiomX has been sold short.

Short Interest Ratio / Days to Cover

BiomX has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BiomX has recently decreased by 20.52%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BiomX insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.17% of the stock of BiomX is held by insiders.

Percentage Held by Institutions

40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHGE Stock Analysis - Frequently Asked Questions

How have PHGE shares performed this year?

BiomX's stock was trading at $0.5870 at the beginning of the year. Since then, PHGE stock has decreased by 34.8% and is now trading at $0.3830.

How were BiomX's earnings last quarter?

BiomX Inc. (NYSEAMERICAN:PHGE) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.03.

How do I buy shares of BiomX?

Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BiomX own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Moderna (MRNA), T2 Biosystems (TTOO), Chegg (CHGG), Aldeyra Therapeutics (ALDX), Nokia (NOK), Avino Silver & Gold Mines (ASM) and Anavex Life Sciences (AVXL).

Company Calendar

• Last Earnings: 11/14/2023
• Today: 7/17/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:PHGE
• CIK: 1739174
• Web: www.biomx.com
• Phone: 972-7-2394-2377
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BiomX: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +3,816.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -919.61%
• Return on Assets: -108.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.35
• Quick Ratio: 3.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 1.28

Miscellaneous

• Outstanding Shares: 26,180,000
• Free Float: 25,870,000
• Market Cap: $10.03 million
• Optionable: N/A
• Beta: 1.41